Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703164 | 1.00 | MPI (0.35) | MPI | |
| SCHEMBL17941696 | 0.94 | MPI (0.36) | MPI | |
| SCHEMBL2295774 | 0.85 | MPI (0.37) | MPI | |
| SCHEMBL1654615 | 0.84 | PAX8 (0.32) | — | |
| SCHEMBL14879229 | 0.81 | MPI (0.35) | MPI | |
| SCHEMBL3486713 | 0.76 | LMNA (0.48) | — | |
| SCHEMBL14921467 | 0.76 | MPI (0.39) | MPI | |
| SCHEMBL4160815 | 0.76 | MPI (0.39) | MPI | |
| SCHEMBL1763816 | 0.76 | MPI (0.39) | MPI | |
| SCHEMBL2634932 | 0.76 | MPI (0.39) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190264203-A1 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10131907-B2 | Glycoconjugates of RNA interference agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20150065558-A1 | Glycoconjugates of RNA Interference Agents | BANK OF AMERICA, N.A. | 2015-03-05 | — | — | US | disclosed |
| US-8877917-B2 | Glycoconjugates of RNA interference agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20090203135-A1 | Glycoconjugates of RNA Interference Agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008131419-A2 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065558-A1 | Glycoconjugates of RNA Interference Agents | RNASE1, B3GAT3, UGCG | MPI 79/4885 |
| US-10131907-B2 | Glycoconjugates of RNA interference agents | RNASE1, B3GAT3, UGCG | MPI 79/4885 |
| US-20190264203-A1 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | RNASE1, B3GAT3, UGCG | MPI 79/4885 |
| US-20090203135-A1 | Glycoconjugates of RNA Interference Agents | RNASE1, B3GAT3, UGCG | MPI 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.